Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Transactivation Assays that Identify Indirect and Direct Activators of Human Pregnane X Receptor (PXR, NR1I2) and Constitutive Androstane Receptor (CAR, NR1I3).

Pinne M, Ponce E, Raucy JL.

Drug Metab Lett. 2017;11(2):128-137. doi: 10.2174/1872312812666171207113639.

PMID:
29219065
2.

Transactivation Assays to Assess Canine and Rodent Pregnane X Receptor (PXR) and Constitutive Androstane Receptor (CAR) Activation.

Pinne M, Ponce E, Raucy JL.

PLoS One. 2016 Oct 12;11(10):e0164642. doi: 10.1371/journal.pone.0164642. eCollection 2016.

3.

Advantages of cell-based high-volume screening assays to assess nuclear receptor activation during drug discovery.

Pinne M, Raucy JL.

Expert Opin Drug Discov. 2014 Jun;9(6):669-86. doi: 10.1517/17460441.2014.913019. Epub 2014 May 12. Review.

PMID:
24819724
4.

Cell-based systems to assess nuclear receptor activation and their use in drug development.

Raucy JL, Lasker JM.

Drug Metab Rev. 2013 Feb;45(1):101-9. doi: 10.3109/03602532.2012.737333. Review.

PMID:
23330544
5.

Utility of DPX2 cells for predicting CYP3A induction-mediated drug-drug interactions and associated structure-activity relationships.

Fahmi OA, Raucy JL, Ponce E, Hassanali S, Lasker JM.

Drug Metab Dispos. 2012 Nov;40(11):2204-11. doi: 10.1124/dmd.112.047456. Epub 2012 Aug 21.

PMID:
22912432
6.

Current in vitro high throughput screening approaches to assess nuclear receptor activation.

Raucy JL, Lasker JM.

Curr Drug Metab. 2010 Nov;11(9):806-14. Review.

PMID:
21189134
7.

Nanosilver particle effects on drug metabolism in vitro.

Lamb JG, Hathaway LB, Munger MA, Raucy JL, Franklin MR.

Drug Metab Dispos. 2010 Dec;38(12):2246-51. doi: 10.1124/dmd.110.035238. Epub 2010 Sep 22.

PMID:
20861156
8.

Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.

Hirani VN, Raucy JL, Lasker JM.

Drug Metab Dispos. 2004 Dec;32(12):1462-7. Epub 2004 Sep 24.

PMID:
15448116
9.

Differences in FMO2*1 allelic frequency between Hispanics of Puerto Rican and Mexican descent.

Krueger SK, Siddens LK, Martin SR, Yu Z, Pereira CB, Cabacungan ET, Hines RN, Ardlie KG, Raucy JL, Williams DE.

Drug Metab Dispos. 2004 Dec;32(12):1337-40. Epub 2004 Sep 8.

PMID:
15355885
10.

Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes.

Raucy JL, Lasker J, Ozaki K, Zoleta V.

Toxicol Sci. 2004 Jun;79(2):233-41. Epub 2004 Mar 31.

PMID:
15056802
11.
12.

Genetic polymorphisms of flavin-containing monooxygenase (FMO).

Krueger SK, Williams DE, Yueh MF, Martin SR, Hines RN, Raucy JL, Dolphin CT, Shephard EA, Phillips IR.

Drug Metab Rev. 2002 Aug;34(3):523-32. Review.

PMID:
12214664
13.

Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes.

Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM.

J Pharmacol Exp Ther. 2002 Aug;302(2):475-82.

PMID:
12130704
14.

Recent advances in P450 research.

Raucy JL, Allen SW.

Pharmacogenomics J. 2001;1(3):178-86. Review.

PMID:
11908754
15.

CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.

Wester MR, Lasker JM, Johnson EF, Raucy JL.

Drug Metab Dispos. 2000 Mar;28(3):354-9.

PMID:
10681382
16.

CYP2E1 expression in human lymphocytes from various ethnic populations.

Raucy JL, Schultz ED, Kearins MC, Arora S, Johnston DE, Omdahl JL, Eckmann L, Carpenter SP.

Alcohol Clin Exp Res. 1999 Dec;23(12):1868-74.

PMID:
10630604
17.

Drug metabolizing enzymes in lymphocytes.

Raucy JL, Ingelman-Sundberg M, Carpenter S, Rannug A, Rane A, Franklin M, Romkes M.

J Biochem Mol Toxicol. 1999;13(3-4):223-6. Review. No abstract available.

PMID:
10098909
18.

Role of human CYP4F2 in hepatic catabolism of the proinflammatory agent leukotriene B4.

Jin R, Koop DR, Raucy JL, Lasker JM.

Arch Biochem Biophys. 1998 Nov 1;359(1):89-98.

PMID:
9799565
19.

Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.

Lasker JM, Wester MR, Aramsombatdee E, Raucy JL.

Arch Biochem Biophys. 1998 May 1;353(1):16-28.

PMID:
9578596
20.

Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity.

Raucy JL, Schultz ED, Wester MR, Arora S, Johnston DE, Omdahl JL, Carpenter SP.

Drug Metab Dispos. 1997 Dec;25(12):1429-35.

PMID:
9394034
21.

Peroxisome proliferator activated receptor-alpha expression in human liver.

Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF.

Mol Pharmacol. 1998 Jan;53(1):14-22.

PMID:
9443928
22.

Human hepatocytes express an array of proinflammatory cytokines after agonist stimulation or bacterial invasion.

Rowell DL, Eckmann L, Dwinell MB, Carpenter SP, Raucy JL, Yang SK, Kagnoff MF.

Am J Physiol. 1997 Aug;273(2 Pt 1):G322-32.

PMID:
9277410
23.

Ethanol-mediated transplacental induction of CYP2E1 in fetal rat liver.

Carpenter SP, Savage DD, Schultz ED, Raucy JL.

J Pharmacol Exp Ther. 1997 Aug;282(2):1028-36.

PMID:
9262372
24.

Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51.

Richardson TH, Griffin KJ, Jung F, Raucy JL, Johnson EF.

Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.

PMID:
9028867
25.

Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases.

Jung F, Richardson TH, Raucy JL, Johnson EF.

Drug Metab Dispos. 1997 Feb;25(2):133-9.

PMID:
9029042
26.

Drug metabolic enzymes in developmental toxicology.

Miller MS, Juchau MR, Guengerich FP, Nebert DW, Raucy JL.

Fundam Appl Toxicol. 1996 Dec;34(2):165-75. Review.

PMID:
8954747
27.
28.
29.

Use of lymphocytes for assessing ethanol-mediated alterations in the expression of hepatic cytochrome P4502E1.

Raucy JL, Curley G, Carpenter SP.

Alcohol Clin Exp Res. 1995 Dec;19(6):1369-75.

PMID:
8749797
30.

A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli.

Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinski CJ, Johnson EF.

Arch Biochem Biophys. 1995 Oct 20;323(1):87-96.

PMID:
7487078
31.

Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9.

Daikh BE, Lasker JM, Raucy JL, Koop DR.

J Pharmacol Exp Ther. 1994 Dec;271(3):1427-33.

PMID:
7996455
32.

Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans.

Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI.

Biochemistry. 1994 Feb 22;33(7):1743-52.

PMID:
8110777
33.

The expression of xenobiotic-metabolizing cytochromes P450 in fetal tissues.

Raucy JL, Carpenter SJ.

J Pharmacol Toxicol Methods. 1993 Jun;29(3):121-8. Review. No abstract available.

PMID:
8364226
34.

Induction of P4502E1 by acetone in isolated rabbit hepatocytes. Role of increased protein and mRNA synthesis.

Kraner JC, Lasker JM, Corcoran GB, Ray SD, Raucy JL.

Biochem Pharmacol. 1993 Apr 6;45(7):1483-92.

PMID:
8471070
35.

Cloning and expression of complementary DNAs for multiple members of the human cytochrome PH50IIC subfamily.

Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA.

Biochemistry. 1993 Feb 9;32(5):1390. No abstract available.

PMID:
8095407
36.

Bioactivation of halogenated hydrocarbons by cytochrome P4502E1.

Raucy JL, Kraner JC, Lasker JM.

Crit Rev Toxicol. 1993;23(1):1-20. Review.

PMID:
8471158
37.

Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol.

Bornheim LM, Lasker JM, Raucy JL.

Drug Metab Dispos. 1992 Mar-Apr;20(2):241-6.

PMID:
1352216
38.

Identification of lanosterol 14 alpha-methyl demethylase in human tissues.

Raucy JL, Carpenter SJ, Trzaskos JM.

Biochem Biophys Res Commun. 1991 May 31;177(1):497-503.

PMID:
2043135
39.

Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.

Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA.

Biochemistry. 1991 Apr 2;30(13):3247-55. Erratum in: Biochemistry. 1993 Feb 9;32(5):1390.

PMID:
2009263
40.

Induction of cytochrome P450IIE1 in the obese overfed rat.

Raucy JL, Lasker JM, Kraner JC, Salazar DE, Lieber CS, Corcoran GB.

Mol Pharmacol. 1991 Mar;39(3):275-80.

PMID:
2005876
41.

Extensive alteration of genomic DNA and rise in nuclear Ca2+ in vivo early after hepatotoxic acetaminophen overdose in mice.

Ray SD, Sorge CL, Tavacoli A, Raucy JL, Corcoran GB.

Adv Exp Med Biol. 1991;283:699-705.

PMID:
2069042
42.

Isolation of P450 enzymes from human liver.

Raucy JL, Lasker JM.

Methods Enzymol. 1991;206:577-87. No abstract available.

PMID:
1664480
43.

Early loss of large genomic DNA in vivo with accumulation of Ca2+ in the nucleus during acetaminophen-induced liver injury.

Ray SD, Sorge CL, Raucy JL, Corcoran GB.

Toxicol Appl Pharmacol. 1990 Nov;106(2):346-51.

PMID:
2256122
44.

Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).

Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M.

Mol Pharmacol. 1990 Aug;38(2):207-13.

PMID:
2385232
45.

Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2.

Raucy JL, Lasker JM, Lieber CS, Black M.

Arch Biochem Biophys. 1989 Jun;271(2):270-83.

PMID:
2729995
46.

Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8.

Leo MA, Lasker JM, Raucy JL, Kim CI, Black M, Lieber CS.

Arch Biochem Biophys. 1989 Feb 15;269(1):305-12.

PMID:
2916844
47.
48.

Supplemental Content

Loading ...
Support Center